Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
about
IgE-based Immunotherapy of Cancer -A Comparative Oncology ApproachPhase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia(®)) in Dogs with Spontaneous Malignancies.Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcomaEffects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.Toxicity and response in cats with neoplasia treated with toceranib phosphate.Macrocytosis secondary to hydroxyurea therapy.Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.Effects of Toceranib Phosphate on the Hypothalamic-Pituitary-Thyroid Axis in Tumor-Bearing Dogs.Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.Skin depigmentation associated with toceranib phosphate in a dog.Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs.Masitinib monotherapy in canine epitheliotropic lymphoma.Injection-Site Sarcoma in a Dog: Clinical and Pathological Findings.Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017)
P2860
Q28655505-A955B54A-8881-468C-BAD2-EC154CF37B59Q33428144-A32D8F36-9159-49DA-BCDC-92036E0A354BQ33431212-3B7416A6-1A8D-4797-984B-9D853D80B613Q33726782-D8ED5BEE-19E8-4CCE-A285-23DCB3239EBDQ35552532-D4D1653F-5EA1-4C29-8043-34B176F92948Q35660360-F7EE5DFF-9DB1-4909-81EB-F3770F096B25Q38737411-D90F997C-5798-4E92-9BF1-83290DF6C551Q38740809-D6FBFAF7-558D-45B2-943F-F90E1C2F31BEQ39698999-0AA8C352-398F-438C-9E13-92BD09731DA1Q40119454-59C0D286-AB4D-41A6-AF55-4E9D72207AD1Q40793870-BCDE7639-2BA2-452E-BDF1-2FCFAF3A5574Q46356093-63EBA24B-9A38-468F-BE9F-E3C423147E12Q47417940-3EFC354B-ECB1-4DA2-9D25-B3FE41634DA2Q48202305-63FF9717-2B19-4F71-A05B-E0B54E523667Q48267612-D6705E62-AE02-424E-B676-DF5283FCD05CQ51779979-9CB96F6D-C665-4A28-A587-BD09A883E0D8Q53524319-0BDD6A59-7AEF-4833-8FB0-66BB3A258AB9Q54978288-11BA9E16-A646-4BA9-8DC9-E9200DABDC6AQ55043104-F86F2470-03CF-49B0-9D0D-4184491D05E7Q55381309-289772CC-D45D-4EC8-AC45-436925D64F57Q57652261-A13354DA-0679-42F9-8790-8ADE7078BF65
P2860
Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Evaluation of the adverse even ...... ow the maximum tolerated dose.
@ast
Evaluation of the adverse even ...... ow the maximum tolerated dose.
@en
type
label
Evaluation of the adverse even ...... ow the maximum tolerated dose.
@ast
Evaluation of the adverse even ...... ow the maximum tolerated dose.
@en
prefLabel
Evaluation of the adverse even ...... ow the maximum tolerated dose.
@ast
Evaluation of the adverse even ...... ow the maximum tolerated dose.
@en
P2093
P2860
P356
P1476
Evaluation of the adverse even ...... ow the maximum tolerated dose.
@en
P2093
Cheryl A London
Luis Feo Bernabe
Mark F Yancey
Michael Pennell
Roberta Portela
Sandra Nguyen
William C Kisseberth
P2860
P2888
P356
10.1186/1746-6148-9-190
P577
2013-09-30T00:00:00Z
P5875
P6179
1004067876